RecruitingNCT05640102
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Studying Waldenström Macroglobulinemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeiGene
- Principal Investigator
- Study DirectorBeiGene
- Intervention
- Zanubrutinib(drug)
- Enrollment
- 111 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (8)
- Clearview Cancer Institute, Huntsville, Alabama, United States
- South Alabama Medical Science Foundation Mitchell Cancer Institute, Mobile, Alabama, United States
- City of Hope National Medical Center, Duarte, California, United States
- Los Angeles Cancer Network (Lacn), Glendale, California, United States
- Eisenhower Medical Center, Lucy Curci Cancer Center, Rancho Mirage, California, United States
- Hattiesburg Hematology and Oncology Clinic, Hattiesburg, Mississippi, United States
- Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
- Pan American Oncology Trials, Llc, Rio Piedras, Puerto Rico
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05640102 on ClinicalTrials.govOther trials for Waldenström Macroglobulinemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07471074Phenotypic and Functional Study of Bone Marrow Mesenchymal Stem Cells in Waldenström MacroglobulinemiaCentre Hospitalier Universitaire, Amiens
- RECRUITINGPHASE2NCT06986174A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaShayna Sarosiek, MD
- RECRUITINGPHASE4NCT07169331A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström MacroglobulinemiaBeiGene
- ACTIVE NOT RECRUITINGPHASE2NCT05952037A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaBeOne Medicines
- RECRUITINGPHASE2NCT05734495Pirtobrutinib and Venetoclax in Waldenström MacroglobulinemiaDana-Farber Cancer Institute
- RECRUITINGNANCT04893564Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström MacroglobulinemiaCentre Hospitalier Universitaire, Amiens
- RECRUITINGNANCT04898647Clinical Study of the Hyperviscosity Syndrome in Waldenström MacroglobulinemiaCentre Hospitalier Universitaire, Amiens
- ACTIVE NOT RECRUITINGPHASE2NCT02180724An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström MacroglobulinemiaAcerta Pharma BV